Peripheral neuropathies after BRAF and/or MEK inhibitors treatment: A pharmacovigilance study

被引：0
|
作者：
Picca, A. [1 ]
Birzu, C. [1 ]
Berzero, G. [2 ]
Sanchez-Pena, P. [3 ]
Gaboriau, L. [4 ]
Vidil, F. [5 ]
Lenglet, T. [6 ]
Tafani, C. [7 ]
Ricard, D. [7 ]
Psimaras, D. [1 ]
Bihan, K. [8 ]
机构：
[1] Sorbonne Univ, Hop Univ 8 La Pitie Salpetriere Charles Foix, Inst Cerveau, AP HP,CNRS,Inserm,UMR S 1127,ICM, Paris, France
[2] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy
[3] CHU Bordeaux, Pole Sante Publ, Serv Pharmacol Med, Bordeaux, France
[4] CHU Lille, Serv Pharmacol Med, Ctr Reg Pharmacovigilance, Lille, France
[5] Agence Natl Securite Medicament & Produits Sante, St Denis, France
[6] GH Pitie Salpetriere, AP HP, Dept Neurophysiol Clin, Paris, France
[7] Hop Instruct Armees Percy, Serv Sante Armees, Dept Neurol, Paris, France
[8] GH Pitie Salpetriere, AP HP, Dept Pharmacol, Ctr Reg Pharmacovigilance, Paris, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2022年 / 36卷
关键词：
neuropathy; polyradiculoneuropathy; BRAF inhibitors; MEK inhibitors; neurotoxicity; melanoma; pharmacovigilance; adverse events;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-089
引用
收藏
页码：139 / 140
页数：2
相关论文
共 50 条
  • [1] Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study
    Picca, Alberto
    Birzu, Cristina
    Berzero, Giulia
    Sanchez-Pena, Paola
    Gaboriau, Louise
    Vidil, Faustine
    Lenglet, Timothee
    Tafani, Camille
    Ricard, Damien
    Psimaras, Dimitri
    Bihan, Kevin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (11) : 4941 - 4949
  • [2] BRAF and MEK inhibitors rechallenge after adverse event in patients with cancer: A pharmacovigilance cohort study
    Ezine, E.
    Joachim, A.
    Baroudjian, B.
    Lebbe, C.
    Dompmartin, A.
    Dolladille, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 124 - 125
  • [3] Peripheral neuropathies under Immune Checkpoint Inhibitors: A pharmacovigilance study
    Ewig, E.
    Fournier, D.
    Palassin, P.
    Cholle, C.
    Bihan, B.
    Lebrun-Vignes, B.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 117 - 118
  • [4] Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma
    Fauviaux, E.
    Promelle, V
    Boucenna, V
    Jany, B.
    Errera, M. H.
    Delbarre, M.
    Boucenna, W.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2022, 45 (06): : 612 - 618
  • [5] Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity
    Senechal, Isabelle
    Andres, Maria Sol
    Tong, Jieli
    Ramalingam, Sivatharshini
    Nazir, Muhummad Sohaib
    Rosen, Stuart D.
    Young, Kate
    Idaikkadar, Praveena
    Larkin, James
    Lyon, Alexander R.
    CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1431 - 1441
  • [6] BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
    Garutti, Mattia
    Bergnach, Melissa
    Polesel, Jerry
    Palmero, Lorenza
    Pizzichetta, Maria Antonietta
    Puglisi, Fabio
    CANCERS, 2023, 15 (01)
  • [7] Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
    Martin, Claire A.
    Cullinane, Carleen
    Kirby, Laura
    Abuhammad, Shatha
    Lelliott, Emily J.
    Waldeck, Kelly
    Young, Richard J.
    Brajanovski, Natalie
    Cameron, Donald P.
    Walker, Rachael
    Sanij, Elaine
    Poortinga, Gretchen
    Hannan, Ross D.
    Pearson, Richard B.
    Hicks, Rodney J.
    McArthur, Grant A.
    Sheppard, Karen E.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (10) : 2139 - 2152
  • [8] Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
    F. Consoli
    M. Bersanelli
    G. Perego
    S. Grisanti
    B. Merelli
    A. Berruti
    F. Petrelli
    Clinical and Translational Oncology, 2020, 22 : 900 - 907
  • [9] Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
    Consoli, F.
    Bersanelli, M.
    Perego, G.
    Grisanti, S.
    Merelli, B.
    Berruti, A.
    Petrelli, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (06): : 900 - 907
  • [10] Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review
    Basilicata, Michele
    Terrano, Vincenzo
    D'Aurelio, Alessandro
    Bruno, Giovanni
    Troiani, Teresa
    Bollero, Patrizio
    Napolitano, Stefania
    HEALTHCARE, 2024, 12 (01)
12345